Assertio Therapeutics (ASRT) Tops Q2 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to Assertio Therapeutics (ASRT) Tops Q2 EPS by 10c

Assertio Reports Second Quarter 2025 Financial Results

August 11, 2025 4:05 PM EDT

Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million

Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy

LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients needs, today reported financial results for the second quarter ended June 30, 2025.

Said Brendan OGrady, Chief Executive Officer, The... More